Metsera

Acquired

Reducing the burden of obesity

New York, United States · Founded 2022 · $505.0M raised

Biotech
Obesity
Headquarters
New York, New York
Employees
11–50
Founded
2022
Business Model
Other
Total Funding
$505.0M
Last Round
$215.0M Series BNov 2024
Rounds
2
Acquired by
PfizerSep 2025

About

Metsera is a clinical-stage biotechnology company focused on developing next-generation oral and injectable nutrient-stimulated hormone (NuSH) therapies for obesity and metabolic diseases. Their portfolio aims to reduce barriers to adoption with improved scalability, potency, and tolerability. Now part of Pfizer following acquisition.

Summary

Metsera is a Biotech company based in New York, United States, founded in 2022. It has raised $505.0M in total across 2 rounds, most recently a $215.0M Series B round in Nov 2024. Investors include Pfizer Ventures, OrbiMed and ARCH Venture Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

AcquisitionSep 2025
$4.9B

Sign up to see all 4 rounds

Seed through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Metsera on Indexed.vc
<a href="https://indexed.vc/companies/metsera"><img src="https://indexed.vc/api/badge/company/metsera" alt="Metsera on Indexed.vc" width="260" height="76" /></a>